DexCom/$DXCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Primary listing
Employees
10,250
Headquarters
Website
DexCom Metrics
BasicAdvanced
$30B
53.30
$1.43
1.45
-
Price and volume
Market cap
$30B
Beta
1.45
52-week high
$93.25
52-week low
$57.52
Average daily volume
4.2M
Financial strength
Current ratio
1.52
Quick ratio
1.302
Long term debt to equity
50.274
Total debt to equity
98.057
Interest coverage (TTM)
36.17%
Profitability
EBITDA (TTM)
923.3
Gross margin (TTM)
58.77%
Net profit margin (TTM)
13.29%
Operating margin (TTM)
15.98%
Effective tax rate (TTM)
27.11%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
6.08%
Return on equity (TTM)
22.83%
Valuation
Price to earnings (TTM)
53.297
Price to revenue (TTM)
6.947
Price to book
11.62
Price to tangible book (TTM)
12.14
Price to free cash flow (TTM)
52.345
Free cash flow yield (TTM)
1.91%
Free cash flow per share (TTM)
1.456
Growth
Revenue change (TTM)
9.30%
Earnings per share change (TTM)
-11.42%
3-year revenue growth (CAGR)
17.17%
10-year revenue growth (CAGR)
29.70%
3-year earnings per share growth (CAGR)
36.59%
10-year earnings per share growth (CAGR)
35.96%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
Bulls say / Bears say
The HHS’s MAHA initiative will roll out a large-scale campaign to raise awareness about wearable health monitoring devices, with Dexcom shares rising in response—signaling potential federal backing to help drive CGM adoption (Reuters)
Dexcom’s move into the underpenetrated Type 2 diabetes segment targets a user group with only 7–8% CGM adoption; analysts expect CGM usage to double within three years, supporting long-term growth prospects (Barron’s)
FDA approval for the G7 15 Day CGM System lengthens sensor wear to 15.5 days and delivers class-leading MARD of 8%, offering greater convenience and differentiating Dexcom ahead of its planned U.S. launch in H2 2025 (Medscape)
CMS’s proposed competitive bidding program for CGMs and insulin pumps could result in substantial Medicare reimbursement cuts for Dexcom and shift business to lower-cost suppliers like Abbott, potentially impacting a mid-teens percentage of Dexcom’s U.S. CGM market as early as 2027 (Reuters)
The FDA sent Dexcom a warning letter in March 2025 for manufacturing and quality system non-compliance at its San Diego and Mesa plants, causing the stock to drop nearly 7% and necessitating expensive corrective measures (Reuters)
During the FDA approval process for the G7 15-Day sensor, Dexcom revealed a 26% failure rate, raising reliability concerns that could slow early user adoption and confidence (FierceBiotech)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $30B as of September 14, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 53.3 as of September 14, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.